[go: up one dir, main page]

UA99598C2 - Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина - Google Patents

Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина

Info

Publication number
UA99598C2
UA99598C2 UAA200901761A UAA200901761A UA99598C2 UA 99598 C2 UA99598 C2 UA 99598C2 UA A200901761 A UAA200901761 A UA A200901761A UA A200901761 A UAA200901761 A UA A200901761A UA 99598 C2 UA99598 C2 UA 99598C2
Authority
UA
Ukraine
Prior art keywords
disorder
prevention
treatment
serotonin
dopamine
Prior art date
Application number
UAA200901761A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кристель ФИОРИНИ-ПЮЙБАРЕ
Бернар ФАБР
Сесиль Шовен
Филипп Жулиа
Original Assignee
Пьер Фабр Медикаман
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пьер Фабр Медикаман filed Critical Пьер Фабр Медикаман
Publication of UA99598C2 publication Critical patent/UA99598C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Данное изобретение касается применения экстракта эвкалипта для получения лекарственного средства или пищевой добавки, предназначенных для лечения и/или профилактики неврологических, психиатрических патологий или заболеваний и связанных с этим расстройств, функциональных соматических синдромов и зависимости от веществ, вызывающих привыкание, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина, где указанный экстракт эвкалипта содержит по меньшей мере одно соединение формулы (I) или какую-либо из его диастереоизомерных форм:, (I)в которой R1 вместе с атомом углерода, с которым он связан, образует группу С=СН, группу,,и R2 означает изобутильную, α-изобутильную или β-изобутильную группу.
UAA200901761A 2006-08-01 2007-07-27 Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина UA99598C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0607201A FR2904557B1 (fr) 2006-08-01 2006-08-01 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques

Publications (1)

Publication Number Publication Date
UA99598C2 true UA99598C2 (ru) 2012-09-10

Family

ID=37708427

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200901761A UA99598C2 (ru) 2006-08-01 2007-07-27 Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина

Country Status (20)

Country Link
US (1) US20090324754A1 (ru)
EP (1) EP2049133A2 (ru)
JP (1) JP2010500974A (ru)
KR (1) KR20090034401A (ru)
CN (1) CN101511378A (ru)
AR (1) AR062165A1 (ru)
AU (1) AU2007283529A1 (ru)
BR (1) BRPI0714863A2 (ru)
CA (1) CA2659162A1 (ru)
FR (1) FR2904557B1 (ru)
IL (1) IL196788A0 (ru)
MA (1) MA30592B1 (ru)
MX (1) MX2009000673A (ru)
NO (1) NO20090951L (ru)
NZ (1) NZ574429A (ru)
RU (1) RU2445112C2 (ru)
TN (1) TN2009000018A1 (ru)
TW (1) TW200820961A (ru)
UA (1) UA99598C2 (ru)
WO (1) WO2008017752A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926547B1 (fr) * 2008-01-18 2010-04-23 Pf Medicament 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments.
JP5602346B2 (ja) 2008-06-17 2014-10-08 株式会社ロッテ ユーカリ抽出物の調製方法
GB2465228A (en) * 2008-11-15 2010-05-19 Athena Health Patents Inc Analogues of phloroglucinols from eucalyptus plant varieties and related compounds and their use in treating neurodegenerative disorders
CN102085169B (zh) * 2011-01-30 2012-08-29 广州中涵生物科技有限公司 一种使黑头溶解同步收细毛孔的制剂
PT106278B (pt) * 2012-04-26 2018-01-03 Raiz Inst De Investigação Da Floresta E Papel Método para a obtenção de um extrato rico em ácidos triterpénicos a partir da casca de eucalipto
KR102115037B1 (ko) * 2013-12-04 2020-05-25 코웨이 주식회사 상고머리 야테 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물
CN106231923A (zh) * 2013-12-18 2016-12-14 斯拉毕思科股份公司 类囊体降低对可口食物欲望的用途
CN109475586A (zh) 2016-06-29 2019-03-15 康纳塞斯创新公司 脱羧的大麻树脂、其用途和制备其的方法
CN109172554A (zh) * 2018-09-06 2019-01-11 淮安安莱生物科技有限公司 大果桉醛c在制备治疗人肝癌的药物方面的应用
KR102212193B1 (ko) 2019-07-15 2021-02-03 박경호 인동등 및 유칼립투스 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329297A1 (fr) * 1975-10-29 1977-05-27 Rougier Yves Inhalateur buccal
JP3365782B2 (ja) * 1990-11-22 2003-01-14 株式会社ロッテ 新規マクロカルパール類及びその製造法
DE4447336C2 (de) * 1994-12-31 1996-12-19 Goebel Hartmut J Dr Med Habil Verwendung eines Gemisches aus Cineol und Menthol
JPH08198765A (ja) * 1995-01-31 1996-08-06 Hayami Kinugawa 鎮痛用医薬組成物
JPH11137232A (ja) * 1997-08-02 1999-05-25 Ever Bright Ind Corp ハーブ製品
US20010036488A1 (en) * 2000-01-18 2001-11-01 Syuichi Hayashi Anti-obestic composition
JP4809980B2 (ja) * 2000-01-18 2011-11-09 長岡香料株式会社 抗動脈硬化症剤
MXPA04006039A (es) * 2001-12-19 2004-09-27 The Quigley Corp Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
JP4979181B2 (ja) * 2003-01-31 2012-07-18 株式会社ヤクルト本社 グリケーション阻害剤及びその利用
JP2005272431A (ja) * 2004-03-24 2005-10-06 Yukio Kitagawa アロマセラピー品

Also Published As

Publication number Publication date
MA30592B1 (fr) 2009-07-01
CN101511378A (zh) 2009-08-19
NZ574429A (en) 2012-01-12
MX2009000673A (es) 2009-02-04
BRPI0714863A2 (pt) 2013-05-21
TW200820961A (en) 2008-05-16
RU2445112C2 (ru) 2012-03-20
CA2659162A1 (fr) 2008-02-14
EP2049133A2 (fr) 2009-04-22
AU2007283529A1 (en) 2008-02-14
FR2904557B1 (fr) 2010-04-30
US20090324754A1 (en) 2009-12-31
WO2008017752A3 (fr) 2008-04-10
FR2904557A1 (fr) 2008-02-08
IL196788A0 (en) 2009-11-18
KR20090034401A (ko) 2009-04-07
RU2009107166A (ru) 2010-09-10
WO2008017752A2 (fr) 2008-02-14
AR062165A1 (es) 2008-10-22
TN2009000018A1 (fr) 2010-08-19
NO20090951L (no) 2009-04-24
JP2010500974A (ja) 2010-01-14

Similar Documents

Publication Publication Date Title
UA99598C2 (ru) Применение экстракта эвкалипта для лечения или профилактики расстройств, являющихся следствием нарушения обратного захвата дофамина и/или серотонина, и/или норадреналина
MXPA05008652A (es) Uso del enantiomero (1s,2r) de milnacipran para la preparacion de un medicamento.
PH12013500809A1 (en) Pharmaceutical composition, methods for treating and uses thereof
TN2011000415A1 (en) Pharmaceutical composition comprising a sglt2 inhibitor a dpp-i v inhibitor and optionally a further antidiabetic agent and uses thereof
GB2487712A8 (en) use of the phtocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
UA100384C2 (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
UA100542C2 (ru) Способ лечения и/или профилактики синдрома слабоумия экстрактом, изготовленным из листьев ginkgo biloba
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
UA84697C2 (ru) Использование (1s,2r) энантиомера милнаципрана для получения лекарственного средства
MX2010002734A (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevencion de perdida auditiva.
ZA200707716B (en) Use of iron (III) complex compounds
MX2014013452A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
WO2011045795A3 (en) Magnesium rich drinking water
WO2011058262A8 (fr) Médicament inhalable à base de xénon pour traiter ou pour prévenir les dyskinésies induites
TW200700071A (en) Novel use
PA8787001A1 (es) " derivados de macrolactona"
TR201820411T4 (tr) Rasetam ve karnitin içeren farmasötik bileşim ve bunun hazırlanış süreci.
EA201001828A1 (ru) Способ синтеза производных 3,6-дигидро-1,3,5-триазина
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
WO2009073138A3 (en) Treatment of metabolic syndrome with novel amides
SG153698A1 (en) Composition and method for prevention and treatment of alzheimeræs disease